Justas2010 (Talk | contribs) |
Justas2010 (Talk | contribs) |
||
Line 22: | Line 22: | ||
<div class="modal-close"></div> | <div class="modal-close"></div> | ||
<div class="modal-content"> | <div class="modal-content"> | ||
− | + | <section class="design_subsections"> | |
− | + | <h1 id="Liposomes">Liposomes</h1> | |
− | + | <div class="third_level_links"> | |
<a href="#Liposomes">Liposomes</a> | <a href="#Liposomes">Liposomes</a> | ||
<a href="#Ribosome_modifications">Ribosome modifications</a> | <a href="#Ribosome_modifications">Ribosome modifications</a> | ||
Line 44: | Line 44: | ||
</p> | </p> | ||
</div> | </div> | ||
− | + | <h2>Requirements for liposomes</h2> | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
<p></p> | <p></p> | ||
<p> | <p> | ||
Line 68: | Line 64: | ||
</p> | </p> | ||
</div> | </div> | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
<h2>Photolithography as a tool for microfluidic chip fabrication</h2> | <h2>Photolithography as a tool for microfluidic chip fabrication</h2> | ||
<p></p> | <p></p> | ||
Line 82: | Line 69: | ||
After calculating the exact parameters for microfluidic channels and receiving a printed photomask, photolithography is performed to create a master for microfluidic chip preparation. After completing this step, PDMS (<var>polydimethylsiloxane</var>) is poured on to the master left in a thermostat overnight. Inlets and outlets are punched with a biopsy puncher, and the PDMS is cleaned and plasma treated before attaching it to the PDMS coated microscope glass slides. Fig. 3 presents a simplified scheme demonstrating photolithography and other +6steps towards creating a microfluidic chip. To learn more details about the fabrication process, refer to <a href="https://2018.igem.org/Team:Vilnius-Lithuania/Protocols">our Protocols</a>. We called our chip LipoDrop. The final form of LipoDrop is shown in Fig. 4. | After calculating the exact parameters for microfluidic channels and receiving a printed photomask, photolithography is performed to create a master for microfluidic chip preparation. After completing this step, PDMS (<var>polydimethylsiloxane</var>) is poured on to the master left in a thermostat overnight. Inlets and outlets are punched with a biopsy puncher, and the PDMS is cleaned and plasma treated before attaching it to the PDMS coated microscope glass slides. Fig. 3 presents a simplified scheme demonstrating photolithography and other +6steps towards creating a microfluidic chip. To learn more details about the fabrication process, refer to <a href="https://2018.igem.org/Team:Vilnius-Lithuania/Protocols">our Protocols</a>. We called our chip LipoDrop. The final form of LipoDrop is shown in Fig. 4. | ||
</p> | </p> | ||
− | |||
− | |||
− | |||
− | |||
<div class="image-container"> | <div class="image-container"> | ||
<img src="https://static.igem.org/mediawiki/2018/7/7d/T--Vilnius-Lithuania--Fig3_Liposomes.png"/> | <img src="https://static.igem.org/mediawiki/2018/7/7d/T--Vilnius-Lithuania--Fig3_Liposomes.png"/> | ||
− | <p><strong>Fig. 3 </strong> Simplified scheme for microfluidic device preparation. <strong>a-b</strong> the silicon wafer is cleaned and spin-coated with photoresist; <strong>c</strong> the photomask is aligned on the sample and exposed to UV light. <strong>d</strong> sample is submerged to a developer – only the sections that were exposed to the UV light remain intact on the wafer; <strong>e</strong> PDMS is poured onto the master to create a PDMS mold and left for a bake in the oven; <strong>f</strong> the mold is then separated and prepared further by cleaning and punching inlets and outlets; <strong>e-f</strong> a microscopic slide is prepared by applying a thin layer of PDMS on top; <strong>i</strong> PDMS mold and PDMS covered microscopic slide are plasma treated and connected to each other to produce a final microfluidic chip.</ | + | <p><strong>Fig. 3 </strong> Simplified scheme for microfluidic device preparation. <strong>a-b</strong> the silicon wafer is cleaned and spin-coated with photoresist; <strong>c</strong> the photomask is aligned on the sample and exposed to UV light. <strong>d</strong> sample is submerged to a developer – only the sections that were exposed to the UV light remain intact on the wafer; <strong>e</strong> PDMS is poured onto the master to create a PDMS mold and left for a bake in the oven; <strong>f</strong> the mold is then separated and prepared further by cleaning and punching inlets and outlets; <strong>e-f</strong> a microscopic slide is prepared by applying a thin layer of PDMS on top; <strong>i</strong> PDMS mold and PDMS covered microscopic slide are plasma treated and connected to each other to produce a final microfluidic chip.</div></p> |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
<div class="image-container"> | <div class="image-container"> | ||
<img src="https://static.igem.org/mediawiki/2018/7/75/T--Vilnius-Lithuania--Fig4_Liposomes.png"/> | <img src="https://static.igem.org/mediawiki/2018/7/75/T--Vilnius-Lithuania--Fig4_Liposomes.png"/> | ||
− | <p><strong>Fig. 4 </strong> Final form of Lipodrop. | + | <p><strong>Fig. 4 </strong> Final form of Lipodrop.</div> |
− | + | ||
− | + | ||
− | + | ||
</p> | </p> | ||
<h2>Coating LipoDrop with PVA</h2> | <h2>Coating LipoDrop with PVA</h2> | ||
Line 110: | Line 86: | ||
</p> | </p> | ||
</div> | </div> | ||
− | |||
<h2>Lipovision software for fully automated microfluidic experiments</h2> | <h2>Lipovision software for fully automated microfluidic experiments</h2> | ||
<p></p> | <p></p> | ||
Line 126: | Line 101: | ||
<p><strong>Fig. 6</strong> A close-up of the phase interface during liposome synthesis; <strong>IA</strong> phase contains elements required for the synthesis | <p><strong>Fig. 6</strong> A close-up of the phase interface during liposome synthesis; <strong>IA</strong> phase contains elements required for the synthesis | ||
and integration of membrane proteins; <strong>LO</strong> phase consists of octanol and lipids that form a lipid bilayer; OA solution | and integration of membrane proteins; <strong>LO</strong> phase consists of octanol and lipids that form a lipid bilayer; OA solution | ||
− | carries surfactants that stabilize the initial formation and propagation of the droplets along the microfluidic device.</p> | + | carries surfactants that stabilize the initial formation and propagation of the droplets along the microfluidic device.</p></div> |
− | + | ||
− | + | ||
− | + | ||
<h2>Optimized flow rates for high throughput synthesis</h2> | <h2>Optimized flow rates for high throughput synthesis</h2> | ||
<p></p> | <p></p> | ||
Line 144: | Line 116: | ||
</div> | </div> | ||
− | |||
− | |||
− | |||
A simple liposome size frequency distribution was determined with an image analysis software ImageJ. A plugin SpotCaliper was utilized to identify circular objects and measure their diameters (Fig. 8a). Gaussian distribution was fitted to the frequency histogram. Results verify that the size of the liposomes follows the Gaussian distribution (Fig. 8b). It proves that the droplets are highly homogeneous. Average diameter of a liposome (results from a single batch experiment) is around 12 µm, with standard deviation of 0.4 µm which fits our requirements very well. | A simple liposome size frequency distribution was determined with an image analysis software ImageJ. A plugin SpotCaliper was utilized to identify circular objects and measure their diameters (Fig. 8a). Gaussian distribution was fitted to the frequency histogram. Results verify that the size of the liposomes follows the Gaussian distribution (Fig. 8b). It proves that the droplets are highly homogeneous. Average diameter of a liposome (results from a single batch experiment) is around 12 µm, with standard deviation of 0.4 µm which fits our requirements very well. | ||
</p> | </p> | ||
Line 157: | Line 126: | ||
</div> | </div> | ||
</p> | </p> | ||
− | |||
<h2>Characterization: encapsulation efficiency and internal synthesis</h2> | <h2>Characterization: encapsulation efficiency and internal synthesis</h2> | ||
<p></p> | <p></p> | ||
Line 176: | Line 144: | ||
</p> | </p> | ||
− | |||
<h2>Characterization: unilamellarity validation using α-hemolysin protein pores</h2> | <h2>Characterization: unilamellarity validation using α-hemolysin protein pores</h2> | ||
<p></p> | <p></p> | ||
Line 199: | Line 166: | ||
</p> | </p> | ||
− | |||
<h3>References</h3> | <h3>References</h3> | ||
<p> | <p> | ||
Line 301: | Line 267: | ||
</li> | </li> | ||
</ol></p> | </ol></p> | ||
− | + | ||
− | + | ||
</div> | </div> | ||
<p>For multi-gene editing, we chose to supply the donor sequence as a linear DNA strand (PCR product). Due to financial reasons, to construct the donor DNA sequence we performed separate PCRs of the homology arms (from the E. coli genome), selection marker (antibiotic resistance genes from available plasmids) (Fig. 4). The oligomers had the his and strep tag sequences incorporated into them alongside 2 different restriction sites. In case the distance between the ribosomes and the membrane wall was too small for our system to be efficient, we also designed alternative variants the would feature the his-tags connected via a highly flexible two-glycine-four-serine linker (GGSSSS), which is a highly popular linker for artificial fusion proteins. | <p>For multi-gene editing, we chose to supply the donor sequence as a linear DNA strand (PCR product). Due to financial reasons, to construct the donor DNA sequence we performed separate PCRs of the homology arms (from the E. coli genome), selection marker (antibiotic resistance genes from available plasmids) (Fig. 4). The oligomers had the his and strep tag sequences incorporated into them alongside 2 different restriction sites. In case the distance between the ribosomes and the membrane wall was too small for our system to be efficient, we also designed alternative variants the would feature the his-tags connected via a highly flexible two-glycine-four-serine linker (GGSSSS), which is a highly popular linker for artificial fusion proteins. | ||
Line 717: | Line 682: | ||
<p>scFv consists of a minimal functional antigen-binding domain of an antibody (~30 kDa) (Fig. 1) , in which the heavy variable chain (VH) and light variable chain (VL) are connected by Ser and Gly rich flexible linker. [1] In most cases scFv is expressed in bacteria, where it is produced in cytoplasm, a reducing environment, in which disulfide bonds are not able to form and protein is quickly degraded or aggregated. Although poor solubility and affinity limit scFvs’ applications, their stability can be improved by merging with other proteins. [2] When expressed in cell free system, scFv should form disulfide bonds with the help of additional molecules. Merging to a membrane protein would provide additional stability and would display scFv on liposome membrane, where its activity could be detected. These improved qualities make ScFv recombinant proteins a perfect tool to evaluate, if SynDrop system acts in an anticipated manner. Of all possible scFvs we decided to use scFv-anti vaginolysin, which binds and neutralizes toxin vaginolysin (VLY). Its main advantage is rapid (< 1 h) and cheap detection of activity by inhibition of erythrocyte lysis (Fig. 2). Looking into future applications, scFvs are also attractive targets of molecular evolution, because one round of evolution would last less than one day thus generating a and wide range of different scFv mutants. Those displaying the highest affinity for antigens could be selected and used as drugs or drug carriers. </p> | <p>scFv consists of a minimal functional antigen-binding domain of an antibody (~30 kDa) (Fig. 1) , in which the heavy variable chain (VH) and light variable chain (VL) are connected by Ser and Gly rich flexible linker. [1] In most cases scFv is expressed in bacteria, where it is produced in cytoplasm, a reducing environment, in which disulfide bonds are not able to form and protein is quickly degraded or aggregated. Although poor solubility and affinity limit scFvs’ applications, their stability can be improved by merging with other proteins. [2] When expressed in cell free system, scFv should form disulfide bonds with the help of additional molecules. Merging to a membrane protein would provide additional stability and would display scFv on liposome membrane, where its activity could be detected. These improved qualities make ScFv recombinant proteins a perfect tool to evaluate, if SynDrop system acts in an anticipated manner. Of all possible scFvs we decided to use scFv-anti vaginolysin, which binds and neutralizes toxin vaginolysin (VLY). Its main advantage is rapid (< 1 h) and cheap detection of activity by inhibition of erythrocyte lysis (Fig. 2). Looking into future applications, scFvs are also attractive targets of molecular evolution, because one round of evolution would last less than one day thus generating a and wide range of different scFv mutants. Those displaying the highest affinity for antigens could be selected and used as drugs or drug carriers. </p> | ||
<div class="image-container"> | <div class="image-container"> | ||
− | <img src="https://static.igem.org/mediawiki/2018/1/16/T--Vilnius-Lithuania--PERMATOMAS_ScFv.png" | + | <img src="https://static.igem.org/mediawiki/2018/1/16/T--Vilnius-Lithuania--PERMATOMAS_ScFv.png"/> |
<p><strong>Fig. 1 </strong>Simplified structure of scFv Antibody</p> | <p><strong>Fig. 1 </strong>Simplified structure of scFv Antibody</p> | ||
</div> | </div> | ||
− | |||
<div class="image-container"> | <div class="image-container"> | ||
− | <img src="https://static.igem.org/mediawiki/2018/9/97/T--Vilnius-Lithuania--Fig2_NEW_real_Surface_scFV.png" | + | <img src="https://static.igem.org/mediawiki/2018/9/97/T--Vilnius-Lithuania--Fig2_NEW_real_Surface_scFV.png"/> |
<p><strong>Fig. 2 </strong>Scheme of scFv_antiVLY and VLY interaction. Left- scFv_antiVLY binds to VLY, erythrocytes stay intact, Right- scFv_antiVLY does not bind and VLY lyse erythrocytes.</p> | <p><strong>Fig. 2 </strong>Scheme of scFv_antiVLY and VLY interaction. Left- scFv_antiVLY binds to VLY, erythrocytes stay intact, Right- scFv_antiVLY does not bind and VLY lyse erythrocytes.</p> | ||
− | </div> | + | </div></p> |
<p></p> | <p></p> | ||
<h1>Results</h1> | <h1>Results</h1> | ||
Line 730: | Line 694: | ||
<div class="image-container"></div> | <div class="image-container"></div> | ||
<p>scFv constructs were created <a href="http://parts.igem.org/Part:BBa_K2622004"> BBa_K2622004</a>. and checked by <a href="https://2018.igem.org/Team:Vilnius-Lithuania/Protocols"> colony PCR and DNA sequencing</a>. scFv synthesis was performed in a cell free system. Validation of protein expression was done by running a sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), see (Fig. 3)</p> | <p>scFv constructs were created <a href="http://parts.igem.org/Part:BBa_K2622004"> BBa_K2622004</a>. and checked by <a href="https://2018.igem.org/Team:Vilnius-Lithuania/Protocols"> colony PCR and DNA sequencing</a>. scFv synthesis was performed in a cell free system. Validation of protein expression was done by running a sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), see (Fig. 3)</p> | ||
− | <img src="https://static.igem.org/mediawiki/2018/8/83/T--Vilnius-Lithuania--_Fig2_Surface-scFv.png" | + | <img src="https://static.igem.org/mediawiki/2018/8/83/T--Vilnius-Lithuania--_Fig2_Surface-scFv.png"> |
− | + | ||
− | + | ||
<p><strong>Fig. 3 </strong> SDS-PAGE of scFv. GFP is used as positive control, C- chaperone DnaK.</p> | <p><strong>Fig. 3 </strong> SDS-PAGE of scFv. GFP is used as positive control, C- chaperone DnaK.</p> | ||
</div> | </div> | ||
Line 738: | Line 701: | ||
<p>Red arrows in the photo indicate scFv anti-vaginolysin (~27 kDa). As successful synthesis was confirmed, the next step was to check if protein folded correctly and was able to bind its antigen - vaginolysin. We examined this by erythrocyte-lysis test, which was performed by comparing erythrocytes incubated with VLY (erythrocytes burst open) and erythrocytes incubated with VLY that was previously incubated with scFv anti-vaginolysin (less or no erythrocyte lysis). Results revealed that scFv binded to vaginolysin and inhibited cell lysis. Graph in (Fig. 4) demonstrates that scFv indeed attenuated the lysis of erythrocytes. These result prove scFv activity in IVTT system.</p> | <p>Red arrows in the photo indicate scFv anti-vaginolysin (~27 kDa). As successful synthesis was confirmed, the next step was to check if protein folded correctly and was able to bind its antigen - vaginolysin. We examined this by erythrocyte-lysis test, which was performed by comparing erythrocytes incubated with VLY (erythrocytes burst open) and erythrocytes incubated with VLY that was previously incubated with scFv anti-vaginolysin (less or no erythrocyte lysis). Results revealed that scFv binded to vaginolysin and inhibited cell lysis. Graph in (Fig. 4) demonstrates that scFv indeed attenuated the lysis of erythrocytes. These result prove scFv activity in IVTT system.</p> | ||
<div class="image-container"> | <div class="image-container"> | ||
− | <img src="https://static.igem.org/mediawiki/2018/7/7b/T--Vilnius-Lithuania--_Fig3_Surface-scFv.png" | + | <img src="https://static.igem.org/mediawiki/2018/7/7b/T--Vilnius-Lithuania--_Fig3_Surface-scFv.png"> |
− | + | ||
<p> | <p> | ||
<p><strong>Fig. 4 </strong> Percentage of erythrocyte lysis at different +/-scFv dilutions.</p> | <p><strong>Fig. 4 </strong> Percentage of erythrocyte lysis at different +/-scFv dilutions.</p> | ||
Line 745: | Line 707: | ||
<p>We then went one step further and constructed MstX-scFv_antiVLY <a href="http://parts.igem.org/Part:BBa_K2622038"> BBa_2622038</a>, fusion protein, aiming to increase the stability of scFv having in mind future applications and experiments of exposing it on liposome surface. Fusion protein was expressed in E.coli cells; yellow to red arrows in (Fig. 5A) indicate MstX-scFv expression after induction with IPTG.</p> | <p>We then went one step further and constructed MstX-scFv_antiVLY <a href="http://parts.igem.org/Part:BBa_K2622038"> BBa_2622038</a>, fusion protein, aiming to increase the stability of scFv having in mind future applications and experiments of exposing it on liposome surface. Fusion protein was expressed in E.coli cells; yellow to red arrows in (Fig. 5A) indicate MstX-scFv expression after induction with IPTG.</p> | ||
<p>Finally, we expressed the protein in a cell free system (Fig. 5B) along with scFv in order to compare how well scFv accomplishes its function alone or binded to other protein. In this case MstX-scFv_antiVLY fusion did not show superior activity than scFv_antiVLY alone (Fig. 6). These results also reveal that scFv_antiVLY is very sensitive and loses its activity with time. Ist and IInd attempts were separated by 1-2 hours. This amount of time is enough to measure decreasing activity. This must be taken into account when performing future experiments.</p> | <p>Finally, we expressed the protein in a cell free system (Fig. 5B) along with scFv in order to compare how well scFv accomplishes its function alone or binded to other protein. In this case MstX-scFv_antiVLY fusion did not show superior activity than scFv_antiVLY alone (Fig. 6). These results also reveal that scFv_antiVLY is very sensitive and loses its activity with time. Ist and IInd attempts were separated by 1-2 hours. This amount of time is enough to measure decreasing activity. This must be taken into account when performing future experiments.</p> | ||
− | <img src="https://static.igem.org/mediawiki/2018/9/9c/T--Vilnius-Lithuania--Fig_4._5._Surface_scFv.png" | + | <img src="https://static.igem.org/mediawiki/2018/9/9c/T--Vilnius-Lithuania--Fig_4._5._Surface_scFv.png"> |
− | + | ||
<p> | <p> | ||
<p><strong>Fig. 5 </strong>A- MstX-scFv_antiVLY expression in Escherichia coli. B- scFv_antiVLY and MstX-scFv_antiVLY expression in cell-free system.</p> | <p><strong>Fig. 5 </strong>A- MstX-scFv_antiVLY expression in Escherichia coli. B- scFv_antiVLY and MstX-scFv_antiVLY expression in cell-free system.</p> | ||
− | <img src="https://static.igem.org/mediawiki/2018/0/0c/T--Vilnius-Lithuania--_Fig6_Surface-scFv.png" | + | <img src="https://static.igem.org/mediawiki/2018/0/0c/T--Vilnius-Lithuania--_Fig6_Surface-scFv.png"> |
− | + | ||
− | + | ||
− | + | ||
<p> | <p> | ||
<p><strong>Fig. 6 </strong> Percentage of erythrocyte lysis at different scFv/MstX-scFv dilutions.</p> | <p><strong>Fig. 6 </strong> Percentage of erythrocyte lysis at different scFv/MstX-scFv dilutions.</p> |
Revision as of 16:06, 8 November 2018
Design and Results
Results
Cell-free, synthetic biology systems open new horizons in engineering biomolecular systems which feature complex, cell-like behaviors in the absence of living entities. Having no superior genetic control, user-controllable mechanisms to regulate gene expression are necessary to successfully operate these systems. We have created a small collection of synthetic RNA thermometers that enable temperature-dependent translation of membrane proteins, work well in cells and display great potential to be transferred to any in vitro protein synthesis system.